Traina, Tiffany Ann

Publications

Sort by

Co-Author Network

selected publications

Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2020 Academic Article GET IT
Times cited: 20
Emerging Novel Therapeutics in Triple-Negative Breast Cancer. Advances in experimental medicine and biology. 2019 Review GET IT
Times cited: 19
Male breast cancer: a disease distinct from female breast cancer. Breast cancer research and treatment. 2018 Review GET IT
Times cited: 135
Reply to K.S. Shohdy et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Letter GET IT
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Clinical breast cancer. 2018 Academic Article GET IT
Times cited: 8
First international TNBC conference meeting report. Breast cancer research and treatment. 2018 Conference Paper GET IT
Times cited: 12
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 292
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast cancer research and treatment. 2018 Review GET IT
Times cited: 6
The Androgen Receptor: Is It a Promising Target?. Annals of surgical oncology. 2017 Review GET IT
Times cited: 20
OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 394
Androgen receptor-positive, triple-negative breast cancer. Cancer. 2017 Academic Article GET IT
Times cited: 10
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 40
Targeting the androgen receptor in triple-negative breast cancer. Current problems in cancer. 2016 Review GET IT
Times cited: 65
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 28
Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review. NPJ breast cancer. 2016 Academic Article GET IT
Times cited: 8
Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis. JAMA oncology. 2016 Review GET IT
Times cited: 107
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 1
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 323
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 68
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 53
Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocrine-related cancer. 2015 Review GET IT
Times cited: 78
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast cancer (Dove Medical Press). 2014 Review GET IT
Times cited: 91
Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 118
Tolerability of chemotherapy in HIV-infected women with breast cancer: are there prognostic implications?. AIDS patient care and STDs. 2014 Academic Article GET IT
Times cited: 17
Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?. Seminars in oncology. 2013 Review GET IT
Times cited: 103
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 520
Advances in molecular and clinical subtyping of breast cancer and their implications for therapy. Surgical oncology clinics of North America. 2013 Review GET IT
Times cited: 28
The role of the androgen receptor in triple-negative breast cancer. Women's health (London, England). 2013 Review GET IT
Times cited: 36
Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Annals of surgical oncology. 2013 Review GET IT
Times cited: 110
Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 19
Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer. 2012 Academic Article GET IT
Times cited: 58
Treatment of Breast Cancer Brain Metastases. Current breast cancer reports. 2011 Academic Article GET IT
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast cancer research and treatment. 2011 Academic Article GET IT
Times cited: 19
Triple-negative breast cancer: adjuvant therapeutic options. Chemotherapy research and practice. 2011 Academic Article GET IT
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clinical breast cancer. 2011 Academic Article GET IT
Times cited: 109
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer. 2011 Academic Article GET IT
Times cited: 14
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 5
The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer. American journal of surgery. 2010 Academic Article GET IT
Times cited: 12
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 77
Determinants of outcome in elderly patients with positive sentinel lymph nodes. American journal of surgery. 2010 Academic Article GET IT
Times cited: 8
Capecitabine dosing is not yet optimized for breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Letter GET IT
Times cited: 2
Bevacizumab for advanced breast cancer. Women's health (London, England). 2010 Review GET IT
Times cited: 4
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast disease. 2010 Academic Article GET IT
Times cited: 25
Triple-negative breast cancer: role of the androgen receptor. Cancer journal (Sudbury, Mass.). 2010 Review GET IT
Times cited: 113
Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer. Annals of surgical oncology. 2009 Academic Article GET IT
Times cited: 14
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 25
Targeting insulin-like growth factor type 1 receptor in cancer therapy. Targeted oncology. 2009 Review GET IT
Times cited: 37
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 42
PIK3CA mutation associates with improved outcome in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 315
Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes. Annals of surgical oncology. 2009 Academic Article GET IT
Times cited: 8
Bevacizumab in the treatment of metastatic breast cancer. Oncology (Williston Park, N.Y.). 2009 Review GET IT
Times cited: 7
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 175
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 60
NCCN Task Force Report: breast cancer in the older woman. Journal of the National Comprehensive Cancer Network : JNCCN. 2008 Review GET IT
Times cited: 51
Bevacizumab for advanced breast cancer. Hematology/oncology clinics of North America. 2007 Review GET IT
Times cited: 26
Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. 2006 GET IT
Times cited: 47
Metastatic colon cancer to the ovaries in a Krukenberg-like pattern. 2005 GET IT
Times cited: 2
Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecologic oncology. 2004 Review GET IT
Times cited: 18
Aromatase inhibitors for hormonal therapy of early-stage breast cancer. Current opinion in investigational drugs (London, England : 2000). 2004 Review GET IT

more ...

less ...

Background

education and training

M.D., Weill Cornell Medical College, Cornell University 1999
B.S., Cornell University 1994

Contact

full name

Tiffany Ann Traina

VIVO Weill Cornell Medical College

Tiffany Ann Traina Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name